# Burosumab for CSHS

> **NCT03993821** · EARLY_PHASE1 · UNKNOWN · sponsor: **Laura Tosi** · enrollment: 1 (estimated)

## Conditions studied

- Cutaneous Skeletal Hypophosphatemia Syndrome (CSHS)
- Epidermal Nevus Syndrome

## Interventions

- **DRUG:** Burosumab

## Key facts

- **NCT ID:** NCT03993821
- **Lead sponsor:** Laura Tosi
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-01
- **Primary completion:** 2022-10-30
- **Final completion:** 2023-03
- **Target enrollment:** 1 (ESTIMATED)
- **Last updated:** 2022-03-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03993821

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03993821, "Burosumab for CSHS". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03993821. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*